Specialized roles for cysteine cathepsins in health and disease

Journal of Clinical Investigation

Volumn 120, Issue 10, 2010, Pages 3421-3431

  Reiser, Jochen ^a   Adair, Brian ^b   Reinheckel, Thomas ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN L; CATHEPSIN V; CYSTEINE; PROTEINASE; ACTIN BINDING PROTEIN; DYNAMIN; SYNPO PROTEIN, HUMAN;

ACUTE PANCREATITIS; ALBERS SCHOENBERG DISEASE; ATHEROSCLEROSIS; BIOSYNTHESIS; BONE DISEASE; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE EXPRESSION; GENE MUTATION; HAIM MUNK SYNDROME; HUMAN; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LUNG DISEASE; LYSOSOME; METABOLIC SYNDROME X; METASTASIS; MOUSE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; PAPILLON LEFEVRE SYNDROME; PATHOPHYSIOLOGY; PHYLOGENETIC TREE; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; PYKNODYSOSTOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYNDROME; ACUTE DISEASE; ANIMAL; CHEMISTRY; ENZYMOLOGY; GENETICS; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PANCREATITIS; PHYSIOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; CATHEPSIN B; CATHEPSIN L; CATHEPSINS; DYNAMINS; HUMANS; MICROFILAMENT PROTEINS; MYOCARDIUM; PANCREATITIS; PROTEIN TRANSPORT; PROTEINURIA; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 77957855881     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42918     Document Type: Review

References (150)

1. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4(7):544-558. (Pubitemid 36781345)
2. Barrett AJ, Rawlings ND. 'Species' of peptidases. Biol Chem. 2007;388(11):1151-1157.
3. Willstätter R, Bamann E. Über die Proteasen der Magenschleimhaut. Erste Abhandlung über die Enzyme der Leukozyten. Hoppe-Seyler's Z Physiol Chem. 1929;180(1-3):127-143.
4. Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 2008;36(Database issue):D320-D325.
5. Wartmann T, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology. 2010;138(2):726-737.
6. Puri N, Roche PA. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. Proc Natl Acad Sci U S A. 2008;105(7):2580-2585.
7. Sever S, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest. 2007;117(8):2095-2104.
8. Faul C, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931-938.
9. Reiser J, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem. 2004;279(33):34827-34832. (Pubitemid 39318116)
10. Goulet B, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell. 2004;14(2):207-219.
11. Alcalay NI, et al. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1. Am J Physiol Renal Physiol. 2008;295(6):F1725-F1734.
12. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387-403. (Pubitemid 46477760)
13. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol. 2003;3(6):472-482. (Pubitemid 37339187)
14. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008;83(1):172-176.
15. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5(1):20-27.
16. Friedrichs B, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest. 2003;111(11):1733-1745.
17. Funkelstein L, et al. Major role of cathepsin L for producing the peptide hormones ACTH, beta-endorphin, and alpha-MSH, illustrated by protease gene knockout and expression. J Biol Chem. 2008;283(51):35652-35659.
18. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie. 2008;90(2):194-207. (Pubitemid 351172569)
19. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764-775.
20. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21(12):3029-3041. (Pubitemid 47565524)
21. Abudula A, Rommerskirch W, Weber E, Gunther D, Wiederanders B. Splice variants of human cathepsin L mRNA show different expression rates. Biol Chem. 2001;382(11):1583-1591.
22. Jean D, Guillaume N, Frade R. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J. 2002;361(pt 1):173-184. (Pubitemid 34171421)
23. Jean D, Rousselet N, Frade R. Cathepsin L expression is up-regulated by hypoxia in human melanoma cells: role of its 5′-untranslated region. Biochem J. 2008;413(1):125-134. (Pubitemid 351946868)
24. Bulynko YA, Hsing LC, Mason RW, Tremethick DJ, Grigoryev SA. Cathepsin L stabilizes the histone modification landscape on the Y chromosome and pericentromeric heterochromatin. Mol Cell Biol. 2006;26(11):4172-4184.
25. Duncan EM, et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell. 2008;135(2):284-294.
26. Zheng XL, Kitamoto Y, Sadler JE. Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed). 2009;1:242-249.
27. Carmona E, et al. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry. 1996;35(25):8149-8157. (Pubitemid 26234914)
28. Schilling K, et al. Selectivity of propeptide-enzyme interaction in cathepsin L-like cysteine proteases. Biol Chem. 2009;390(2):167-174.
29. Coulombe R, Grochulski P, Sivaraman J, Menard R, Mort JS, Cygler M. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J. 1996;15(20):5492-5503. (Pubitemid 26385609)
30. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001;20(17):4629-4633. (Pubitemid 32848615)
31. Quraishi O, et al. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry. 1999;38(16):5017-5023. (Pubitemid 129514772)
32. LaLonde JM, et al. The crystal structure of human procathepsin K. Biochemistry. 1999;38(3):862-869.
33. Sivaraman J, Nagler DK, Zhang R, Menard R, Cygler M. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine. J Mol Biol. 2000;295(4):939-951.
34. Kaulmann G, Palm GJ, Schilling K, Hilgenfeld R, Wiederanders B. The crystal structure of a Cys25 -> Ala mutant of human procathepsin S elucidates enzyme-prosequence interactions. Protein Sci. 2006;15(11):2619-2629.
35. Tao K, Stearns NA, Dong J, Wu QL, Sahagian GG. The proregion of cathepsin L is required for proper folding, stability, and ER exit. Arch Biochem Biophys. 1994;311(1):19-27. (Pubitemid 24190097)
36. Vernet T, et al. Processing of the papain precursor. The ionization state of a conserved amino acid motif within the Pro region participates in the regulation of intramolecular processing. J Biol Chem. 1995;270(18):10838-10846.
37. Kreusch S, et al. An evolutionarily conserved tripartite tryptophan motif stabilizes the prodomains of cathepsin L-like cysteine proteases. Eur J Biochem. 2000;267(10):2965-2972.
38. Schilling K, Pietschmann S, Fehn M, Wenz I, Wiederanders B. Folding incompetence of cathepsin L-like cysteine proteases may be compensated by the highly conserved, domain-building N-terminal extension of the proregion. Biol Chem. 2001;382(5):859-865. (Pubitemid 32631726)
39. Baranski TJ, Faust PL, Kornfeld S. Generation of a lysosomal enzyme targeting signal in the secretory protein pepsinogen. Cell. 1990;63(2):281-291. (Pubitemid 20355449)
40. Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim Biophys Acta. 2009;1793(4):605-614.
41. Mach L, Mort JS, Glossl J. Noncovalent complexes between the lysosomal proteinase cathepsin B and its propeptide account for stable, extracellular, high molecular mass forms of the enzyme. J Biol Chem. 1994;269(17):13036-13040.
42. Menard R, et al. Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro. J Biol Chem. 1998;273(8):4478-4484.
43. Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells. J Cell Biol. 2002;159(4):625-635.
44. Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell. 2001;106(2):157-169. (Pubitemid 32772627)
45. Muntener K, Zwicky R, Csucs G, Rohrer J, Baici A. Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death. J Biol Chem. 2004;279(39):41012-41017.
46. Lohmuller T, et al. Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol Chem. 2003;384(6):899-909.
47. Chiari H. Über die Selbstverdauung des menschlichen Pankreas. Zeitschrift für Heilkunde. 1896;17:69-96.
48. Chen JM, Ferec C. Chronic pancreatitis: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2009;10:63-87.
49. Greenbaum LM, Hirshkowitz A, Shoichet I. The activation of trypsinogen by cathepsin B. J Biol Chem. 1959;234:2885-2890.
50. Figarella C, Miszczuk-Jamska B, Barrett AJ. Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler. 1988;369 suppl:293-298.
51. Bode W, Huber R. Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. FEBS Lett. 1976;68(2):231-236.
52. Van Acker GJ, Saluja AK, Bhagat L, Singh VP, Song AM, Steer ML. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol. 2002;283(3):G794-G800.
53. Halangk W, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest. 2000;106(6):773-781.
54. van Acker GJ, Perides G, Steer ML. Co-localization hypothesis: a mechanism for the intrapancreatic activation of digestive enzymes during the early phases of acute pancreatitis. World J Gastroenterol. 2006;12(13):1985- 1990.
55. Lerch MM, Saluja AK, Runzi M, Dawra R, Steer ML. Luminal endocytosis and intracellular targeting by acinar cells during early biliary pancreatitis in the opossum. J Clin Invest. 1995;95(5):2222-2231.
56. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003;22(2-3):271-286.
57. Hook V, Funkelstein L, Lu D, Bark S, Wegrzyn J, Hwang SR. Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. Annu Rev Pharmacol Toxicol. 2008;48:393-423. (Pubitemid 351738159)
58. Yasothornsrikul S, et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A. 2003;100(16):9590-9595.
59. Hwang SR, et al. Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion. J Biol Chem. 2007;282(13):9556-9563.
60. Mareninova OA, et al. Impaired autophagic flux mediates acinar cell vacuole formation and trypsinogen activation in rodent models of acute pancreatitis. J Clin Invest. 2009;119(11):3340-3355.
61. Ravikumar B, et al. Mammalian macroautophagy at a glance. J Cell Sci. 2009;122(pt 11):1707-1711.
62. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7(8):589-600. (Pubitemid 44325350)
63. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358(13):1370- 1380.
64. Nishino I, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406(6798):906-910.
65. Maron BJ, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009;301(12):1253-1259.
66. Tanaka Y, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 2000;406(6798):902-906. (Pubitemid 30664267)
67. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol. 2006;406:554-565.
68. Cheng XW, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension. 2006;48(5):979-987.
69. Stypmann J, et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A. 2002;99(9):6234-6239. (Pubitemid 34493295)
70. Petermann I, et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J. 2006;20(8):1266-1268.
71. Tang Q, et al. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med. 2009;87(3):249-260.
72. Reinheckel T, et al. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci. 2005;118(pt 15):3387-3395.
73. Dennemarker J, et al. Impaired turnover of autophagolysosomes in cathepsin L deficiency. Biol Chem. 2010;391(8):913-922.
74. Dennemarker J, et al. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene. 2010;29(11):1611-1621.
75. Spira D, et al. Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J Biol Chem. 2007;282(51):37045-37052.
76. Everts V, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res. 2006;21(9):1399-1408.
77. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000; 19(6):1187-1194.
78. Maciewicz RA, Etherington DJ. A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J. 1988;256(2):433-440.
79. Schenke-Layland K, et al. Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J. 2009;30(18):2254-2265.
80. Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol. 2008;45(4):514-522.
81. Chavakis E, Koyanagi M, Dimmeler S. Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. Circulation. 2010;121(2):325-335.
82. Urbich C, et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med. 2005;11(2):206-213. (Pubitemid 40321357)
83. Urbich C, Dernbach E, Rossig L, Zeiher AM, Dimmeler S. High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells. J Mol Cell Cardiol. 2008;45(3):429-436.
84. Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet. 2000;24(4):333-335.
85. Kaplan JM, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251-256.
86. Kestila M, et al. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575-582.
87. Hinkes B, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397-1405.
88. Boute N, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24(4):349-354. (Pubitemid 30187431)
89. Winn MP, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005;308(5729):1801-1804.
90. Reiser J, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet. 2005;37(7):739-744.
91. Brown EJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010;42(1):72-76.
92. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int. 2010;77(7):571-580.
93. Shih NY, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286(5438):312-315.
94. Defilippi P, et al. p125FAK tyrosine phosphorylation and focal adhesion assembly: studies with phosphotyrosine phosphatase inhibitors. Exp Cell Res. 1995;221(1):141-152.
95. Kirchhausen T. Three ways to make a vesicle. Nat Rev Mol Cell Biol. 2000;1(3):187-198.
96. Schafer DA. Regulating actin dynamics at membranes: a focus on dynamin. Traffic. 2004;5(7):463-469.
97. Aramburu J, Heitman J, Crabtree GR. Calcineurin: a central controller of signalling in eukaryotes. EMBO Rep. 2004;5(4):343-348.
98. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109 suppl:S67-S79.
99. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2005;6(9):1539-1549.
100. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2(7880):556-560.
101. Audard V, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int. 2006;69(12):2251-2260. (Pubitemid 43882113)
102. Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57-63. (Pubitemid 46138361)
103. Chen D, et al. Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol. 2003;14(3):690-698. (Pubitemid 36246013)
104. Heit JJ, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443(7109):345-349.
105. Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. NFATc1 Balances Quiescence and Proliferation of Skin Stem Cells. Cell. 2008;132(2):299-310.
106. Igarashi P, Somlo S. Polycystic kidney disease. J Am Soc Nephrol. 2007;18(5):1371-1373.
107. Sansregret L, Nepveu A. The multiple roles of CUX1: insights from mouse models and cell-based assays. Gene. 2008;412(1-2):84-94.
108. McGrath ME. The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct. 1999;28:181-204.
109. Turk D, et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 2001;20(23):6570-6582. (Pubitemid 33134188)
110. Erickson AH. Biosynthesis of lysosomal endopeptidases. J Cell Biochem. 1989;40(1):31-41.
111. Garnero P, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347-32352. (Pubitemid 29177183)
112. Mason RW. Emerging functions of placental cathepsins. Placenta. 2008;29(5):385-390.
113. Bethel PA, et al. Design of selective Cathepsin inhibitors. Bioorg Med Chem Lett. 2009;19(16):4622-4625.
114. Viken MK, et al. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. Hum Immunol. 2007;68(9):748-755.
115. Zeeuwen PL, et al. Colocalization of cystatin M/E and cathepsin V in lamellar granules and corneodesmosomes suggests a functional role in epidermal differentiation. J Invest Dermatol. 2007;127(1):120-128.
116. Haider AS, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126(4):869-881.
117. Hagemann S, et al. The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol. 2004;83(11-12):775-780. (Pubitemid 40123841)
118. Sevenich L, Pennacchio LA, Peters C, Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biol Chem. 2006;387(7):885-891. (Pubitemid 44100235)
119. Toomes C, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet. 1999;23(4):421-424.
120. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A. 1999;96(15):8627-8632.
121. Saftig P, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453-13458. (Pubitemid 28522993)
122. Gowen M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654-1663. (Pubitemid 29455813)
123. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236-1238.
124. Potts W, et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol. 2004;85(2):85-96.
125. Kitamoto S, et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation. 2007;115(15):2065-2075. (Pubitemid 46625958)
126. Lutgens E, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation. 2006;113(1):98-107.
127. Sukhova GK, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111(6):897-906. (Pubitemid 37074965)
128. Gocheva V, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20(5):543-556.
129. Vasiljeva O, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66(10):5242-5250. (Pubitemid 43844948)
130. Gondi CS, et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 2004;64(12):4069-4077.
131. Tummalapalli P, et al. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol. 2007;31(5):1039-1050.
132. Sevenich L, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A. 2010;107(6):2497-2502.
133. Gocheva V, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24(3):241-255.
134. Maehr R, et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest. 2005;115(10):2934-2943. (Pubitemid 41434421)
135. Yang M, et al. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol. 2008;28(12):2202-2208.
136. Huang X, Vaag A, Carlsson E, Hansson M, Ahren B, Groop L. Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes. Diabetes. 2003;52(9):2411-2418. (Pubitemid 37059514)
137. Perdereau C, Godat E, Maurel MC, Hazouard E, Diot E, Lalmanach G. Cysteine cathepsins in human silicotic bronchoalveolar lavage fluids. Biochim Biophys Acta. 2006;1762(3):351-356. (Pubitemid 43172851)
138. Hornung V, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847-856.
139. Srivastava M, et al. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respir Res. 2008;9:54.
140. Buhling F, et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol. 2004;164(6):2203-2216. (Pubitemid 38669366)
141. Guttentag S, Robinson L, Zhang P, Brasch F, Buhling F, Beers M. Cysteine protease activity is required for surfactant protein B processing and lamellar body genesis. Am J Respir Cell Mol Biol. 2003;28(1):69-79.
142. Honey K, et al. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat Immunol. 2002;3(11):1069-1074.
143. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002;168(6):2618-2625.
144. Nakagawa T, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998;280(5362):450-453.
145. Nakagawa TY, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999;10(2):207-217.
146. Tolosa E, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest. 2003;112(4):517-526. (Pubitemid 38056336)
147. Dejica VM, et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol. 2008;173(1):161-169.
148. Schurigt U, et al. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum. 2008;58(2):422-434. (Pubitemid 351294877)
149. Svelander L, et al. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol. 2009;613(1-3):155-162.
150. Asagiri M, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008;319(5863):624-627.